108 related articles for article (PubMed ID: 26976325)
1. The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma.
McCormick PN; Fletcher PJ; Wilson VS; Remington GJ
Life Sci; 2016 Apr; 151():300-304. PubMed ID: 26976325
[TBL] [Abstract][Full Text] [Related]
2. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
McCormick PN; Fletcher PJ; Wilson VS; Browne JD; Nobrega JN; Remington GJ
Neuropharmacology; 2015 Feb; 89():225-31. PubMed ID: 25283483
[TBL] [Abstract][Full Text] [Related]
3. Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat.
Bertz JW; Chen J; Woods JH
Psychopharmacology (Berl); 2015 Jan; 232(1):209-21. PubMed ID: 24985891
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
5. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
6. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
Fenu S; Espa E; Pisanu A; Di Chiara G
Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
[TBL] [Abstract][Full Text] [Related]
7. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
[TBL] [Abstract][Full Text] [Related]
8. Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
Lehr E
Psychopharmacology (Berl); 2002 Oct; 163(3-4):495-500. PubMed ID: 12373450
[TBL] [Abstract][Full Text] [Related]
9. Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats.
Johnson PS; Madden GJ; Brewer AT; Pinkston JW; Fowler SC
Psychopharmacology (Berl); 2011 Jan; 213(1):11-8. PubMed ID: 20814781
[TBL] [Abstract][Full Text] [Related]
10. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats.
Breuer ME; Groenink L; Oosting RS; Buerger E; Korte M; Ferger B; Olivier B
Eur J Pharmacol; 2009 Aug; 616(1-3):134-40. PubMed ID: 19549514
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of atipamezole, yohimbine and tolazoline for alpha-2 adrenergic receptor subtypes: implications for clinical reversal of alpha-2 adrenergic receptor mediated sedation in sheep.
Schwartz DD; Clark TP
J Vet Pharmacol Ther; 1998 Oct; 21(5):342-7. PubMed ID: 9811433
[TBL] [Abstract][Full Text] [Related]
13. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice.
Villégier AS; Drouin C; Bizot JC; Marien M; Glowinski J; Colpaërt F; Tassin JP
Synapse; 2003 Dec; 50(4):277-84. PubMed ID: 14556232
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist.
Pertovaara A; Haapalinna A; Sirviö J; Virtanen R
CNS Drug Rev; 2005; 11(3):273-88. PubMed ID: 16389294
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.
Wei SZ; Yao XY; Wang CT; Dong AQ; Li D; Zhang YT; Ren C; Zhang JB; Mao CJ; Wang F; Liu CF
Brain Res Bull; 2021 Dec; 177():363-372. PubMed ID: 34699917
[TBL] [Abstract][Full Text] [Related]
19. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.
Piercey MF; Walker EL; Feldpausch DL; Camacho-Ochoa M
Neurosci Lett; 1996 Nov; 219(2):138-40. PubMed ID: 8971799
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole upregulates dopamine receptor D₂ and D₃ expression in rat striatum.
Tokunaga N; Choudhury ME; Nishikawa N; Nagai M; Tujii T; Iwaki H; Kaneta M; Nomoto M
J Pharmacol Sci; 2012; 120(2):133-7. PubMed ID: 22986363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
